RecruitingNot ApplicableNCT06283251

PediRISE Feasibility

Pilot Randomized Pediatric RISE (Resource Intervention to Support Equity) Feasibility Study


Sponsor

Dana-Farber Cancer Institute

Enrollment

40 participants

Start Date

May 15, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this research study is to learn whether investigators can successfully give the PediRISE program to families-in other words, whether most families are interested in participating in a study about the PediRISE program, including a 50-50 chance of receiving standard usual care, and a 50-50 chance of receiving the PediRISE support program. The names of the study groups in this research study are: * PediRISE Program Group * Usual Care Group


Eligibility

Max Age: 17 Years

Inclusion Criteria16

  • Cohort 1: Poverty-exposed children with cancer receiving front-line cancer-directed therapy
  • Child diagnosed with de novo cancer
  • Child has established care at a study site and initiated cancer directed therapy in the prior 2-months
  • Child planned to receive at least 4-months of cancer-directed therapy at study site from time of diagnosis per initial cancer treatment plan
  • Child is \<18 years at time of enrollment
  • Parent/guardian screened positive for self-reported low-income (\<200% FPL)
  • Family primary residence in CA, CT, MA, ME, NH, NJ, NY or RI
  • Provider approval for permission to approach
  • Cohort 2: Poverty-exposed children with cancer undergoing HSCT
  • Child undergoing allogeneic HSCT for treatment of cancer
  • Child has established care at a study site and is between 30 days prior to start of planned conditioning through day +7 of HSCT at time of enrollment
  • Child planned to receive follow-up care after discharge for HSCT at study site
  • Child is \<18 years at the time of enrollment
  • Parent/guardian screen positive for self-reported low-income (\<200% FPL)
  • Family primary residence in CA, CT, MA, ME, NH, NJ, NY or RI
  • Provider approval for permission to approach

Exclusion Criteria11

  • Cohort 1: Poverty-exposed children with cancer receiving front-line cancer-directed therapy
  • Planned transfer of child to a non-DFCI or non-Columbia facility for cancer-directed therapy
  • Foreign national family receiving care as an Embassy-pay patient
  • Child is enrolled on embedded correlative health equity aims of open or upcoming clinical drug trials which are powered on descriptive parent-reported poverty data (e.g. AALL1731, DFCI 25-001). Co-enrollment on a poverty intervention study would confound the specified endpoints of these open trial correlative studies
  • Child or household member receiving SSI
  • Cohort 2: Poverty-exposed children with cancer undergoing HSCT
  • Planned transfer of child to a non-DFCI, non-Columbia, or non UCSF facility for cancer-directed therapy
  • Foreign national family receiving care as an Embassy-pay patient
  • Child is enrolled on embedded correlative health equity aims of open or upcoming clinical drug trials which are powered on descriptive parent-reported poverty data (e.g. AALL1731, DFCI 25-001). Co-enrollment on a poverty intervention study would confound the specified endpoints of these open trial correlative studies
  • Child previously received RISE intervention
  • Child or household member receiving SSI

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALPediRISE Resource Program

A centrally administered, income-poverty targeted intervention that includes twice-monthly direct provision of unrestricted cash transfers along with benefits counseling to mitigate the risk of loss of means-tested benefits. Funds will be dispersed to families via provided debit card or through personal banking, PayPal, or Venmo.


Locations(4)

University of California San Francisco

San Francisco, California, United States

Boston Children's Hospital

Boston, Massachusetts, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Columbia University Medical Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06283251


Related Trials